Related Experiment Video
Updated: Aug 15, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)
Fabiano de Oliveira Poswar1,2,3,4, Johanna Henriques Nehm1, Francyne Kubaski5
1Clinical Research Group in Medical Genetics, Clinical Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Abstract:
Mucopolysaccharidosis VII (MPS VII, Sly syndrome) is an ultra-rare lysosomal disease caused by a deficiency of the enzyme β-glucuronidase (GUS). The diagnosis is suspected based on a range of symptoms that are common to many other MPS types, and it is confirmed through biochemical and molecular studies. Besides supportive treatment, current and emerging treatments include enzyme replacement therapy, hematopoietic stem cell transplantation, and gene therapy. This review summarizes the clinical manifestations, diagnosis, and emerging treatments for MPS VII.
Related Concept Videos
Lysosomal Hydrolases
Cystic Fibrosis: Management
Sinus disease and chronic...
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Cardiomyopathy V: Interprofessional Care

